Evidence map›Paper›PMID 30526504›Full record

ArticleBMC infectious diseases2018

Human monoclonal anti-protective antigen antibody for the low-dose post-exposure prophylaxis and treatment of Anthrax.

Qi Tang, Siping Xiong, Xudong Liang, Xingwang Kuai, Yiwen Wang, Changjun Wang, Zhenqing Feng, Jin Zhu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Qi TangKey Laboratory of Antibody Technique of National Health and Family Planning Commission, Nanjing Medical University, Nanjing, 210029, China.
Siping XiongKey Laboratory of Antibody Technique of National Health and Family Planning Commission, Nanjing Medical University, Nanjing, 210029, China.
Xudong LiangNational Institute for Communicable Disease Control and Prevention, Chinese Centre for Disease Control and Prevention, Beijing, 102206, China.
Xingwang KuaiKey Laboratory of Antibody Technique of National Health and Family Planning Commission, Nanjing Medical University, Nanjing, 210029, China.
Yiwen WangHuadong Medical Institute of Biotechniques, No.293 Zhongshan Dong Road, Nanjing, 210002, China.
Changjun WangHuadong Medical Institute of Biotechniques, No.293 Zhongshan Dong Road, Nanjing, 210002, China.
Zhenqing FengKey Laboratory of Antibody Technique of National Health and Family Planning Commission, Nanjing Medical University, Nanjing, 210029, China. Fengzhenqing@njmu.edu.cn.
Jin ZhuKey Laboratory of Antibody Technique of National Health and Family Planning Commission, Nanjing Medical University, Nanjing, 210029, China. zhujin1968@njmu.edu.cn.
National Health and Family Planning Commission · CNHuadong Hospital · CNNational Institute for Communicable Disease Control and Prevention · CN

Funding

the National Natural Science Foundation of China 31170884
6 · The paper itself

Abstract

backgroundDisease caused by Bacillus anthracis is often accompanied by high mortality primarily due to toxin-mediated injury. In the early disease course, anthrax toxins are secreted; thus, antibiotic use is limited to the early stage. In this regard, antibodies against the toxin component, protective antigen (PA), play an important role in protecting against anthrax. Therefore, we developed PA21, a fully human anti-PA immunoglobulin G monoclonal antibody.

methodsCombining human Fab was screened from a phage library with human heavy constant regions. Enzyme-linked immune sorbent assay, Western blot analysis and immunoprecipitation test evaluated the binding ability of PA21. Moreover, the affinity and neutralizing activity of the antibody was detected in vitro while the protective effectiveness in 60 rats was also examined in vivo.

resultsThe Fischer 344 rats challenged with the lethal toxin can be protected by PA21 at a concentration of 0.067 mg/kg. All six rats remained alive although PA21 was injected 24 h before the toxin challenge. PA21 did not influence the binding of PA to cell receptors and that of a lethal factor to PA.

conclusionThe PA21 monoclonal antibody against PA can be used for emergency prophylaxis and anthrax treatment.

Indexed as

AnimalsAnthraxAntibodies, BacterialAntibodies, MonoclonalAntigens, BacterialBacillus anthracisBacterial ToxinsCells, CulturedExotoxinsFemaleHumansMicePost-Exposure ProphylaxisRatsRats, Inbred F344anthrax toxinAntibodies, BacterialAntibodies, MonoclonalAntigens, BacterialBacterial ToxinsExotoxinsAnthraxFull human antibodyLethal toxinNeutralisingProtective antigen (PA)

Identifiers

PMID30526504
PMCPMC6288905
OpenAlexW2905557379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.